vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $26.9M, roughly 1.4× WEST BANCORPORATION INC). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -3.7%, a 42.9% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 16.6%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-5.8M). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs 17.0%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
GYRE vs WTBA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $26.9M |
| Net Profit | $-1.4M | $10.6M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 50.0% |
| Net Margin | -3.7% | 39.2% |
| Revenue YoY | 33.4% | 16.6% |
| Net Profit YoY | -340.1% | 34.8% |
| EPS (diluted) | $-0.01 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $37.2M | $24.2M | ||
| Q3 25 | $30.6M | $25.0M | ||
| Q2 25 | $26.8M | $23.8M | ||
| Q1 25 | $22.1M | $23.1M | ||
| Q4 24 | $27.9M | $20.9M | ||
| Q3 24 | $25.5M | $20.3M | ||
| Q2 24 | $25.2M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $-1.4M | $7.4M | ||
| Q3 25 | $5.9M | $9.3M | ||
| Q2 25 | $1.6M | $8.0M | ||
| Q1 25 | $3.7M | $7.8M | ||
| Q4 24 | $569.0K | $7.1M | ||
| Q3 24 | $2.9M | $6.0M | ||
| Q2 24 | $4.5M | $5.2M |
| Q1 26 | — | — | ||
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — |
| Q1 26 | — | 50.0% | ||
| Q4 25 | 0.3% | 39.6% | ||
| Q3 25 | 22.7% | 45.8% | ||
| Q2 25 | 8.1% | 43.4% | ||
| Q1 25 | 10.3% | 43.4% | ||
| Q4 24 | 2.4% | 30.9% | ||
| Q3 24 | 16.6% | 36.6% | ||
| Q2 24 | 12.7% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | -3.7% | 30.7% | ||
| Q3 25 | 19.4% | 37.3% | ||
| Q2 25 | 5.9% | 33.5% | ||
| Q1 25 | 16.9% | 34.0% | ||
| Q4 24 | 2.0% | 34.0% | ||
| Q3 24 | 11.2% | 29.3% | ||
| Q2 24 | 18.0% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $-0.01 | $0.44 | ||
| Q3 25 | $0.03 | $0.55 | ||
| Q2 25 | $0.00 | $0.47 | ||
| Q1 25 | $0.00 | $0.46 | ||
| Q4 24 | $0.00 | $0.41 | ||
| Q3 24 | $0.01 | $0.35 | ||
| Q2 24 | $0.01 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $270.7M |
| Total Assets | $166.1M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $52.4M | $471.1M | ||
| Q3 25 | $60.0M | $232.9M | ||
| Q2 25 | $54.4M | $345.2M | ||
| Q1 25 | $29.9M | — | ||
| Q4 24 | $26.7M | $243.5M | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $25.1M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $106.0M | $266.0M | ||
| Q3 25 | $101.9M | $255.1M | ||
| Q2 25 | $92.0M | $240.9M | ||
| Q1 25 | $68.1M | $237.9M | ||
| Q4 24 | $63.3M | $227.9M | ||
| Q3 24 | $63.2M | $235.4M | ||
| Q2 24 | $60.4M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $166.1M | $4.1B | ||
| Q3 25 | $159.4M | $4.0B | ||
| Q2 25 | $152.6M | $4.1B | ||
| Q1 25 | $129.8M | $4.0B | ||
| Q4 24 | $125.4M | $4.0B | ||
| Q3 24 | $125.2M | $4.0B | ||
| Q2 24 | $120.9M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $12.9M |
| Free Cash FlowOCF − Capex | $-5.8M | $12.4M |
| FCF MarginFCF / Revenue | -15.5% | 46.0% |
| Capex IntensityCapex / Revenue | 0.4% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $-5.6M | $46.5M | ||
| Q3 25 | $4.7M | $11.4M | ||
| Q2 25 | $2.1M | $13.5M | ||
| Q1 25 | $-129.0K | $9.7M | ||
| Q4 24 | $-2.8M | $39.8M | ||
| Q3 24 | $1.7M | $12.9M | ||
| Q2 24 | $-5.5M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | $-5.8M | $43.2M | ||
| Q3 25 | $4.0M | $10.8M | ||
| Q2 25 | $1.8M | $12.8M | ||
| Q1 25 | $-251.0K | $8.3M | ||
| Q4 24 | $-2.8M | $13.7M | ||
| Q3 24 | $1.0M | $7.0M | ||
| Q2 24 | $-6.9M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | -15.5% | 178.3% | ||
| Q3 25 | 13.1% | 43.0% | ||
| Q2 25 | 6.8% | 53.6% | ||
| Q1 25 | -1.1% | 35.7% | ||
| Q4 24 | -10.1% | 65.6% | ||
| Q3 24 | 4.1% | 34.2% | ||
| Q2 24 | -27.5% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 0.4% | 13.7% | ||
| Q3 25 | 2.2% | 2.6% | ||
| Q2 25 | 1.0% | 3.2% | ||
| Q1 25 | 0.6% | 6.5% | ||
| Q4 24 | 0.2% | 125.3% | ||
| Q3 24 | 2.7% | 29.4% | ||
| Q2 24 | 5.8% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | 0.79× | 1.23× | ||
| Q2 25 | 1.32× | 1.70× | ||
| Q1 25 | -0.03× | 1.24× | ||
| Q4 24 | -4.85× | 5.61× | ||
| Q3 24 | 0.60× | 2.17× | ||
| Q2 24 | -1.21× | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
